91̽»¨

University 91̽»¨
  2. About
  3. Find staff
  4. Johan Stranne

Johan Stranne

Professor/ Chief Physician

Department of Urology
Telephone
+46 709-55 88 65
Mail
johan.stranne@gu.se
Visiting address
Bruna stråket 11b V 2 SU/Sahlgrenska
41345 Göteborg
Postal address
Sahlgrenska Universitetssjukhuset
41345 Göteborg

About Johan Stranne

About Johan Stranne Johan Stranne Professor of urology and head of Dept. of Urology, Inst. of Clinical Scienses, Sahlgrenska Academy. Senior Consultant at the department of Urology, Sahlgrenska University Hospital.

Research areas: Prostate cancer and benign prostate enlargement. Focus on surgical treatment and quality of life. Clinically, Johan Stranne works as a Senior Consultant at the Prostate Cancer Center at Sahlgrenska University Hospital, focusing on robot-assisted surgery.

Research environment Johan Stranne is leading a research group consisting of three PhD-students, Dr Katarina Koss Modig, registered nurse Annelie Khatami and Dr Anders Andreasson, a PostDoc Dr Elin Axén and an Associate Professor, Dr Rebecka Arnsrud Godtman. The work focuses on how to maximize the efficacy of surgery while minimizing side effects. Johan Stranne has also, for 20 years, been part of Professor Jonas Hugosson's research group with studies on screening and early detection of prostate cancer. Outside the academy/hospital, Johan Stranne is also an active member of some major multicenter studies on prostate cancer treatment, such as the SPCG 15 study (SPCG - the Scandinavian prostate cancer group), the SPCG 17-study and the LAPPRO study (SSORG - The Scandinavian Surgical Outcomes Research Group). He has been part of these studies/networks for several years.

Background Prostate cancer is, although it can only affect half the population, the most common form of cancer in Sweden and affects more than 10,000 men annually. Every year, over 3,500 Swedish men and an unknown, but large, number of additional men around the world undergo radical prostatectomy. Most of them through robotic assisted laparoscopic technology (RALP). In a large Swedish study of over 4000 men, the so-called LAPPRO study, we have been able to show that about 19% still had a troublesome urinary leak after 2 years. These men's quality of life is also largely linked to the degree of their urinary leakage. In the LAPPRO study we have also shown that how the operation is performed, as well as who performs the operation, affects the risk of urinary leakage and that the patient's age and possibly. Urinary leakage before surgery affects the risk. Thus, there is room for improvement. The goal of the research program is to evaluate and develop current surgical methods, as well as identify those patients who need an increased risk of complications and poorer quality of life and thereby be able to advise better and provide support and assistance with before, during and after treatments. The aim is to create better care for a very large patient group for a long time to come.

Some ongoing projects:

1. Incontinence Post robot assisted radical prostatectomy, Anatomical and functional causes (IPA) (ISRCTN67297115) In order to minimize the risk of incontinence after radical prostatectomy, we must first fully evaluate how the pelvic floor and the muscles around the urethra work and how they are affected by the operation. In this prospective observational study, we examine patients who are scheduled for RALP with magnetic resonance tomography, ultrasound and functional examinations before, and three months after, surgery. The procedure is also filmed. The goal is to then be able to go back and compare data on those patients who leak urine with those who do not leak. The study has started at Sahlgrenska but more centers will join now and the goal is to include a total of 800 patients.

2. Gothenburg Screening Study 2 (G2) () The G2 study is a study in which 40,000 randomly selected men in Gothenburg and the surrounding area are offered to participate. The purpose of the study is to detect prostate cancer early and thereby reduce the risk of dying of prostate cancer. The study is conducted at the Sahlgrenska Academy, University 91̽»¨ and is a collaboration between the Departments of Urology and Radiology. Professor Jonas Hugosson is responsible for the study.

3. Primary surgery or radiotherapy for locally advanced prostate cancer - an open randomized clinical trial (SPCG 15) Patients with locally advanced prostate cancer are randomized between radiation and neoadjuvant hormone therapy or prostatectomy with lymph node dissection and radiotherapy if needed. Primary outcome is cancer-specific mortality. Secondary outcomes are metastasis-free survival, functional problems after treatment and cost effectiveness. The study is a Nordic multicenter study conducted within the Scandinavian prostate cancer network (SPCG).

4. Robotic surgery for prostate cancer, LAParoscopic Prostatectomy Robot or Open (LAPPRO) The LAPPRO study is a national, prospective, non-randomized multicenter study that compares open and robot assisted radical prostatectomy for prostate cancer in terms of oncological and functional outcomes. Twelve Swedish clinics have included patients, five using robotic assisted technology and seven using open technology. The aim is to compare the techniques in terms of short- and long-term results, cost efficiency and quality of life. The study is headed by Professor Eva Haglind

Co-workers in the projects Rebecka Arnsrud Godtman Jonas Hugosson Elin Axén Katarina Koss Brave Marianne Månsson Ann Carlstrand Eva Haglind Olof Akre

Ongoing PhD projects: Head supervisor: Katarina Koss Modig Annelie Khatami

Deputy supervisor: Daniel Ã…hs

Some partners: Olof Akre, Department of Urology, KI Eva Haglind, Department of Clinical 91̽»¨s, GU, Antti Rannikko, Helsinki University Hospital, Finland Klaus Brasso, Copenhagen Prostate Cancer Center and Dep. of Urology, Rigshospitalet Copenhagen, Denmark, Anna Bill-Axelson, University of Uppsala.

Some financiers of the projects ALF FOU Västra Götaland Prostatacancerförbundet Percy Falcks Foundation The Swedish Research Council, Cancerfonden